S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
OTCMKTS:MEOBF

Mesoblast (MEOBF) Stock Forecast, Price & News

$0.35
-0.50 (-58.82%)
(As of 08/4/2023)
Compare
Today's Range
$0.35
▼
$0.35
50-Day Range
$0.35
▼
$1.00
52-Week Range
$0.35
▼
$1.00
Volume
2,000 shs
Average Volume
1,950 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest

MEOBF stock logo

About Mesoblast (OTCMKTS:MEOBF) Stock

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

MEOBF Price History

MEOBF Stock News Headlines

January 11, 2023 | finance.yahoo.com
Mesoblast Limited (MEOBF) Stock Historical Prices & Data - Yahoo Finance
September 29, 2022 | reuters.com
MESO.O - Mesoblast limited (ADR) | Stock Price & Latest News | Reuters
August 14, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 29, 2022 | investing.com
Mesoblast Teva Starts
September 1, 2022 | seekingalpha.com
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
September 1, 2022 | seekingalpha.com
Mesoblast Limited 2022 Q4 - Results - Earnings Call Presentation
May 25, 2022 | markets.businessinsider.com
MindMed Appoints Schond L. Greenway As CFO
May 25, 2022 | benzinga.com
Mesoblast (OTC:MEOBF), Short Interest Report
August 14, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 25, 2022 | benzinga.com
Mesoblast (OTC:MEOBF), Earnings Estimates, EPS, and Revenue
April 29, 2022 | seekingalpha.com
Mesoblast reports FQ3 results
March 28, 2022 | fool.com
Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript
August 31, 2021 | markets.businessinsider.com
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
August 24, 2021 | finance.yahoo.com
Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term
July 19, 2021 | finance.yahoo.com
Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
July 18, 2021 | benzinga.com
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
July 15, 2021 | finance.yahoo.com
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
July 1, 2021 | finance.yahoo.com
Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
June 30, 2021 | finance.yahoo.com
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
June 25, 2021 | finance.yahoo.com
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
June 2, 2021 | finance.yahoo.com
Operational Highlights and Financial Results for the Period Ended March 31, 2021
June 2, 2021 | markets.businessinsider.com
Mesoblast Corporate Update and Financial Results Webcast
May 25, 2021 | finance.yahoo.com
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
May 3, 2021 | finance.yahoo.com
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?
April 30, 2021 | feeds.benzinga.com
Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress
March 30, 2021 | finance.yahoo.com
Mesoblast Operational Highlights and Upcoming Milestones
March 29, 2021 | finance.yahoo.com
Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board
See More Headlines
Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MEOBF
CUSIP
N/A
CIK
1345099
Web
www.mesoblast.com
Phone
(139) 639-6036
Fax
N/A
Employees
77
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 66)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
    Comp: $942.58k
  • Dr. Eric A. Rose M.D. (Age 72)
    Chief Medical Officer & Exec. Director
    Comp: $378.88k
  • Dr. Philip R. Krause M.B.A.
    M.D., M.S., Strategic Advisor & Director
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Fin. Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A. (Age 59)
    M.S., Chief Operating Officer
  • Mr. Peter T. Howard B.Sc. (Age 55)
    L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec.
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster M.B.A. (Age 46)
    MS, BSc, MBA, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing

Key Competitors

View All Competitors













MEOBF Stock - Frequently Asked Questions

How have MEOBF shares performed in 2023?

Mesoblast's stock was trading at $0.5749 at the start of the year. Since then, MEOBF stock has decreased by 39.1% and is now trading at $0.35.
View the best growth stocks for 2023 here.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 2,660,500 shares, an increase of 600.7% from the July 15th total of 379,700 shares. Based on an average trading volume of 900 shares, the days-to-cover ratio is presently 2,956.1 days.
View Mesoblast's Short Interest.

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $0.35.

How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036.

This page (OTCMKTS:MEOBF) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -